BioSpace News Archive

Actinogen Medical Limited (ASX: ACW) announces the full enrollment of 167 participants in the Company’s XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD).

NeuroSense Therapeutics Ltd. announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+ , a leader in precision medicine for psychiatry and neurology.

Cidara Therapeutics, Inc. today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20.

Jaguar planning to begin commercial launch of FDA-approved Gelclair prescription gel for oral mucositis in Q3 2024.

ImmunoPrecise Antibodies Ltd. has recently announced an expansion of its already successful LENSai TM Platform.

Global DNA Nanotechnology Market is valued at US$ 4.34 Bn in 2023, and it is expected to reach US$ 24.29 Bn by 2031, with a CAGR of 24.67% during the forecast period of 2024-2031.

KalVista Pharmaceuticals, Inc. announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately.

BioNTech SE will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

SNIPR Biome ApS (“SNIPR”) announces today that it has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to co-fund a Phase 1b/2a clinical trial in hematological cancer patients.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.